{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:23:19Z","timestamp":1790014999605,"version":"4.0.1"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T00:00:00Z","timestamp":1512000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0188899","type":"journal-article","created":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T23:16:31Z","timestamp":1512083791000},"page":"e0188899","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":68,"title":["First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-\u03b22), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5766-2617","authenticated-orcid":true,"given":"Norbert","family":"Pfeiffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogomil","family":"Voykov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Renieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Weigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagen","family":"Thieme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Feindor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Wosikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Janicot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"P\u00e4ckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"R\u00f6mmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Mala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Fettes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,11,30]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"HA Quigley","year":"2006","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"ref2","first-page":"887","article-title":"Glaucoma is second leading cause of blindness globally","volume":"82","author":"S Kingman","year":"2004","journal-title":"Bulletin of the World Health Organization"},{"issue":"9","key":"ref3","first-page":"CD004399","article-title":"Medical versus surgical interventions for open angle glaucoma","author":"J Burr","year":"2012","journal-title":"The Cochrane database of systematic reviews"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archopht.116.2.241","article-title":"Initial treatment for open-angle glaucoma- medical, laser, or surgical? Surgery is the treatment of choice for open-angle glaucoma","volume":"116","author":"R Hitchings","year":"1998","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0039-6257(03)00038-9","article-title":"Antifibrotics and wound healing in glaucoma surgery","volume":"48","author":"PJ Lama","year":"2003","journal-title":"Surv Ophthalmol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.2147\/OPTH.S29909","article-title":"Comparative study between trabeculectomy with photodynamic therapy (BCECF-AM) and trabeculectomy with antimetabolite (MMC) in the treatment of primary open angle glaucoma","volume":"6","author":"AM Saeed","year":"2012","journal-title":"Clinical ophthalmology"},{"key":"ref7","first-page":"1945","article-title":"A review of the efficacy of mitomycin C in glaucoma filtration surgery","volume":"9","author":"A Al Habash","year":"2015","journal-title":"Clinical ophthalmology"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.5005\/jp-journals-10008-1159","article-title":"Modulation in Glaucoma Filtration Surgery-Conventional Practices and New Perspectives: The Role of Antifibrotic Agents (Part I)","volume":"8","author":"JC Fan Gaskin","year":"2014","journal-title":"Journal of current glaucoma practice"},{"issue":"8","key":"ref9","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3928\/1542-8877-19980801-04","article-title":"Three-year follow-up of trabeculectomies performed with different concentrations of mitomycin-C","volume":"29","author":"H Mietz","year":"1998","journal-title":"Ophthalmic surgery and lasers"},{"issue":"30","key":"ref10","doi-asserted-by":"crossref","first-page":"12468","DOI":"10.1073\/pnas.0705226104","article-title":"TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts","volume":"104","author":"V Damiano","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"ref11","first-page":"279","article-title":"The pathogenic role of transforming growth factor-beta2 in glaucomatous damage to the optic nerve head","volume":"347","author":"R Fuchshofer","year":"2011","journal-title":"Exp Eye Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.exer.2015.08.014","article-title":"The role of astrocytes in optic nerve head fibrosis in glaucoma","volume":"142","author":"M Schneider","year":"2016","journal-title":"Exp Eye Res"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s004170000241","article-title":"Transforming growth factor-beta 2 levels in aqueous humor of glaucomatous eyes","volume":"239","author":"M Inatani","year":"2001","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3341\/kjo.2006.20.3.162","article-title":"Transforming growth factor-beta levels in human aqueous humor of glaucomatous, diabetic and uveitic eyes","volume":"20","author":"SH Min","year":"2006","journal-title":"Korean J Ophthalmol"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0021-5155(01)00523-8","article-title":"Higher concentration of transforming growth factor-beta in aqueous humor of glaucomatous eyes and diabetic eyes","volume":"46","author":"Y Ochiai","year":"2002","journal-title":"Jpn J Ophthalmol"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1089\/jop.2010.0100","article-title":"Influence of race and age on aqueous humor levels of transforming growth factor-beta 2 in glaucomatous and nonglaucomatous eyes","volume":"27","author":"RH Trivedi","year":"2011","journal-title":"Journal of ocular pharmacology and therapeutics: the official journal of the Association for Ocular Pharmacology and Therapeutics"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.exer.2008.11.025","article-title":"Structural changes of the trabecular meshwork in different kinds of glaucoma","volume":"88","author":"OY Tektas","year":"2009","journal-title":"Exp Eye Res"},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","first-page":"8287","DOI":"10.1167\/iovs.11-8218","article-title":"Quantitative Proteomics: TGF{beta}2 Signaling in Trabecular Meshwork Cells","volume":"52","author":"KE Bollinger","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1167\/iovs.06-0226","article-title":"Bone morphogenetic protein-7 is an antagonist of transforming growth factor-beta2 in human trabecular meshwork cells","volume":"48","author":"R Fuchshofer","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2\u20133","key":"ref20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/jop.2013.0220","article-title":"The role of TGF-beta2 and bone morphogenetic proteins in the trabecular meshwork and glaucoma","volume":"30","author":"RJ Wordinger","year":"2014","journal-title":"Journal of ocular pharmacology and therapeutics: the official journal of the Association for Ocular Pharmacology and Therapeutics"},{"issue":"2","key":"ref21","first-page":"20","article-title":"Potent and selective antisense oligonucleotides targeting the transforming growth factor beta (TGF-\u03b2) isoforms in advanced glaucoma: a preclinical evaluation","volume":"2","author":"K Hasenbach","year":"2016","journal-title":"Journal for Modeling in Ophthalmology"},{"key":"ref22","unstructured":"Hasenbach K, Herrnberger L, Kuespert S, R. F, Korhonen H, Wosikowski K, et al., editors. Targeting Transforming Growth Factor beta 2 (TGF-\u03b22) Isoform with ISTH0036\u2014a Potent and Selective Antisense OligonucLeotide\u2014for the Treatment of Glaucoma. ARVO; 2015; Denver, USA."},{"key":"ref23","unstructured":"Wosikowski K, Van Hove I, Puranen J, de Groef L, Haapaniemi AM, Sergeys J, et al., editors. Targeting Transforming Growth Factor beta 2 (TGF-\u03b22) mRNA with ISTH0036 as Novel Therapeutic Intervention in Neovascular Ocular Disease. The Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2017; Baltimore, MD."},{"key":"ref24","unstructured":"Wosikowski K, Hasenbach K, Allais L, Fant P, Bellebeau F, Truchot N, et al., editors. Preclinical Profile of ISTH0036, a Potent and Selective Antisense Oligonucleotide Targeting Transforming Growth Factor beta 2 (TGF-\u03b22) for the Treatment of Ophthalmic Diseases. The Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2015; Denver, CO."},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00055735-199804000-00002","article-title":"Classification of filtering blebs in trabeculectomy: biomicroscopy and functionality","volume":"9","author":"G Picht","year":"1998","journal-title":"Current opinion in ophthalmology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.2147\/OPTH.S67730","article-title":"Subconjunctival bevacizumab to augment trabeculectomy with mitomycin C in the management of failed glaucoma surgery","volume":"8","author":"AM Saeed","year":"2014","journal-title":"Clinical ophthalmology"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"e0171636","DOI":"10.1371\/journal.pone.0171636","article-title":"Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide\/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma","volume":"12","author":"K Lorenz","year":"2017","journal-title":"PLoS One"},{"issue":"18","key":"ref28","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"RN Weinreb","year":"2014","journal-title":"JAMA"},{"issue":"6","key":"ref29","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/bjophthalmol-2011-301132","article-title":"The role of transforming growth factor beta in glaucoma and the therapeutic implications","volume":"97","author":"MA Prendes","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13073-015-0183-x","article-title":"Restoration of mesenchymal retinal pigmented epithelial cells by TGFbeta pathway inhibitors: implications for age-related macular degeneration","volume":"7","author":"MJ Radeke","year":"2015","journal-title":"Genome medicine"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/IJG.0b013e318285fd7d","article-title":"Using the early postoperative intraocular pressure to predict pressure control after a trabeculectomy","volume":"23","author":"S Okimoto","year":"2014","journal-title":"J Glaucoma"},{"issue":"10","key":"ref32","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.ophtha.2007.03.050","article-title":"A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy","volume":"114","author":"P Khaw","year":"2007","journal-title":"Ophthalmology"},{"key":"ref33","first-page":"189","article-title":"Minimally invasive glaucoma surgery: current status and future prospects","volume":"10","author":"GM Richter","year":"2016","journal-title":"Clinical ophthalmology"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0079-6123(08)01117-5","article-title":"Modulation of wound healing during and after glaucoma surgery","volume":"173","author":"S Georgoulas","year":"2008","journal-title":"Progress in brain research"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ophtha.2008.09.049","article-title":"The singapore 5-Fluorouracil trabeculectomy study: effects on intraocular pressure control and disease progression at 3 years","volume":"116","author":"TT Wong","year":"2009","journal-title":"Ophthalmology"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2174\/1874364101610010068","article-title":"Current and Future Techniques in Wound Healing Modulation after Glaucoma Filtering Surgeries","volume":"10","author":"MB Masoumpour","year":"2016","journal-title":"The open ophthalmology journal"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archopht.1997.01100160139001","article-title":"A Long-term Dose-Response Study of Mitomycin in Glaucoma Filtration Surgery","volume":"115","author":"AL Robin","year":"1997","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"ref38","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/S0161-6420(00)00391-2","article-title":"Trabeculectomy with intraoperative mitomycin C versus 5-fluorouracil. Prospective randomized clinical trial","volume":"107","author":"K Singh","year":"2000","journal-title":"Ophthalmology"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0161-6420(95)31051-2","article-title":"5-Fluorouracil and mitomycin C in pseudophakic patients","volume":"102","author":"KA Lamping","year":"1995","journal-title":"Ophthalmology"},{"issue":"4","key":"ref40","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0002-9394(02)01627-6","article-title":"A prospective randomized trial comparing intraoperative 5-fluorouracil vs mitomycin C in primary trabeculectomy","volume":"134","author":"D WuDunn","year":"2002","journal-title":"American journal of ophthalmology"},{"issue":"7","key":"ref41","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/S0161-6420(02)01069-2","article-title":"Efficacy and Safety of Mitomycin-C in Primary Trabeculectomy","volume":"109","author":"R Bindlish","year":"2002","journal-title":"Ophthalmology"},{"issue":"8","key":"ref42","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/ceo.12097","article-title":"Mitomycin C versus5-fluorouracil as an adjunctive treatment for trabeculectomy: a meta-analysis of randomized clinical trials","volume":"41","author":"LI De Fendi","year":"2013","journal-title":"Clinical & Experimental Ophthalmology"},{"issue":"2","key":"ref43","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jss.2008.04.023","article-title":"The role of vascular endothelial growth factor in wound healing","volume":"153","author":"P Bao","year":"2009","journal-title":"J Surg Res"},{"issue":"2","key":"ref44","doi-asserted-by":"crossref","first-page":"e88403","DOI":"10.1371\/journal.pone.0088403","article-title":"Anti-VEGF agents with or without antimetabolites in trabeculectomy for glaucoma: a meta-analysis","volume":"9","author":"Q Xiong","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"ref45","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/IJG.0b013e3181d9ce12","article-title":"Combined intravitreal bevacizumab and trabeculectomy with mitomycin C versus trabeculectomy with mitomycin C alone for neovascular glaucoma","volume":"20","author":"Y Takihara","year":"2011","journal-title":"J Glaucoma"},{"issue":"3","key":"ref46","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/eye.2012.291","article-title":"Can early postoperative intraocular pressure predict success following mitomycin-C augmented trabeculectomy in primary angle-closure glaucoma","volume":"27","author":"SS Rong","year":"2013","journal-title":"Eye"},{"issue":"3","key":"ref47","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/jcp.10378","article-title":"Transforming growth factor-beta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases","volume":"197","author":"CN Nagineni","year":"2003","journal-title":"J Cell Physiol"},{"issue":"7","key":"ref48","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.2337\/db08-1008","article-title":"The transforming growth factor-beta pathway is a common target of drugs that prevent experimental diabetic retinopathy","volume":"58","author":"C Gerhardinger","year":"2009","journal-title":"Diabetes"},{"issue":"5","key":"ref49","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1172\/JCI114065","article-title":"Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye","volume":"83","author":"TB Connor Jr.","year":"1989","journal-title":"J Clin Invest"},{"key":"ref50","first-page":"706","article-title":"The roles of signaling pathways in epithelial-to-mesenchymal transition of PVR","volume":"21","author":"Z Chen","year":"2015","journal-title":"Mol Vis"},{"issue":"2","key":"ref51","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.exer.2008.10.016","article-title":"Posterior capsule opacification","volume":"88","author":"IM Wormstone","year":"2009","journal-title":"Exp Eye Res"},{"issue":"5","key":"ref52","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ajo.2010.11.008","article-title":"Transforming growth factor-beta signaling pathway activation in Keratoconus","volume":"151","author":"C Engler","year":"2011","journal-title":"American journal of ophthalmology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0188899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T19:27:38Z","timestamp":1660073258000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0188899"}},"subtitle":[],"editor":[{"given":"Gianni","family":"Virgili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,11,30]]},"references-count":52,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0188899","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,30]]}}}